

Selected Publications for Dr. Pedram Argani

1. **Argani P**, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts: evidence for a biologic distinction. *Cancer* 2001;91: 1332-1341.
2. Tascilar M, Offerhaus GJA, Altink R, **Argani P**, Sohn TA, Yeo CJ, Cameron JL, Goggins M, Hruban RH, Wilentz RE. Immunohistochemical labeling for Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. *Am J Clin Pathol* 2001; 116: 831-7.
3. Abraham SC, Lee JH, Boitnott JK, **Argani P**, Furth EE, Wu TT. Microsatellite instability in intraductal papillary neoplasms of the biliary tract. *Mod Pathol* 2002; 15: 1309-1317.
4. Sahin F, Maitra A, **Argani P**, Sato N, Maehara N, Montgomery E, Goggins M, Hruban RH, Su GH. Loss of STK11/LKB1 expression in pancreatic and biliary neoplasms. *Mod Pathol* 2003; 16: 686-691.
5. Abraham SC, Cruz-Correa M, **Argani P**, Furth EE, Hruban RH, Boitnott JK. Lymphoplasmacytic chronic cholecystitis in patients with lymphoplasmacytic sclerosing pancreatitis. *Am J Surg Pathol* 2003; 27: 441-451.
6. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Shulick R, Ku J-L, Park J-G, Miyazaki K, Ashfaq R, Wistuba II, Geradts J, **Argani P**, Maitra A. Identification of Novel Cellular Targets in Biliary Tract Cancers using Global Gene Expression Technology. *Am J Pathol.* 2003; 163: 217-219.
7. Siegelman SS. Nephrogenic rests mimicking Wilms' tumor on CT and MRI. *Pediatr Radiol* 2004; 34: 152-155.
8. Abraham SC, Lee J-H, Hruban RH, **Argani P**, Furth EE, Wu T-T. Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. *Hum Pathol* 2003; 34: 902-910.
9. Swierczynski S, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH, **Argani P**. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. *Hum Pathol* 2004; 35: 357-66.
10. Kristiansen TZ, Bunkebborg J, Gronborg M, Molina H, Thulavath PJ, **Argani P**, Goggins MG, Maitra A, Pandey A. A proteomic analysis of human bile. *Mol Cell Proteomics* 2004; 3: 715-728.
11. Koopman J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, **Argani P**, Hidalgo M, Iacobelli S, Goggins M, Maitra A. Mac-2 binding protein is a diagnostic marker of biliary tract cancer. *Cancer* 2004; 101: 1609-1615.
12. Hustinx SR, Hruban RH, Leoni LM, Iacobuzio-Donahue C, Cameron JL, Yeo CJ, Brown PN, **Argani P**, Asfaq R, Fukushima N, Goggins M, Kern SE, Maitra A. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. *Cancer Biol Ther* 2005; 4: e50-3.
13. Alvarez H, Corvalan A, Roa JC, **Argani P**, Murillo F, Edwards J, Beaty R, Feldmann G, Hong S-M, Mullendore M, Roa I, Ibanez L, Pimentel F, Diaz A, Riggins GJ, Maitra A. Serial Analysis of Gene Expression

(SAGE) identifies connective tissue growth factor (CTGF) expression as a prognostic biomarker in gallbladder carcinoma. *Clin Cancer Res* 2008; 14: 2631-8.

14. Shi C, Chandrasekharan A, Thuluvath PJ, Karikari C, **Argani P**, Goggins M, Maitra A, Eshleman JR. Ultrasensitive detection of KRAS2 mutations in bile and serum of patients with biliary tract carcinoma using LigAmp technology. *J Mol Diagn* 2009; 11: 583-9.
15. Singhi AD, Adsay NV, Swierczynski SL, Torbenson M, Anders RA, Hruban RH, **Argani P**. Hyperplastic Luschka ducts: a mimic of adenocarcinoma in the gallbladder fossa. *Am J Surg Pathol* 2011;35: 883-890.
16. Bai H, Gayyed MF, Lam-Himlin DM, Klein AP, Nayar SK, Xu Y, Khan M, **Argani P**, Pan D, Anders RA. Expression of Yes associated protein, YAP, modulates Survivin expression in primary liver malignancies. *Human Pathology* 2012;43: 1376-1385.
17. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, **Argani P**, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nat Genet.* 2013 Dec;45(12):1470-3
18. Luchini C, Robertson SA, Hong SM, Felsenstein M, Anders RA, Pea A, Nottegar A, Veronese N, He J, Weiss MJ, Capelli P, Scarpa A, **Argani P**, Kapur P, Wood LD. PBRM1 loss is a late event during the development of cholangiocarcinoma. *Histopathology.* 2017;71: 375-382.
19. **Argani P**, Palsgrove DN, Anders RA, Smith SC, Saoud C, Kwon R, Voltaggio L, Assarzagdegan N, Oshima K, Rooper L, Matoso A, Zhang L, Cantarel BL, Gagan J, Antonescu CR.. A Novel *NIPBL-NACCI* Gene Fusion Is Characteristic of the Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma *Am J Surg Pathol.* 2021;45:1550-1560.
20. Lee JW, Zhang Y, Yoshizawa T, **Argani P**, Wood LD, Oshima K. Cancerization of ducts in hilar cholangiocarcinoma *Virchows Arch.* 2022 481:1-10